Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Beta-lactam Infusion in Severe Pneumonia
NCT05102162Phase 4Terminated
- Sponsor
- University of Florida
- Start
- Dec 2021
- Primary completion
- Feb 2023
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of meropenem, cefepime, piperacillin + tazobactam in pneumonia, sponsored by University of Florida. Started Dec 2021; status: terminated.
02
Drugs
meropenemcefepimepiperacillin + tazobactam
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT05102162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102162.